Brain scans aim to uncover hidden risk in Parkinson's patients
NCT ID NCT07213219
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study will use PET-MRI brain scans to compare the reward system in 44 Parkinson's patients, some of whom have a sleep disorder called RBD. The goal is to understand why some patients develop impulse control problems, like gambling or compulsive behaviors, as a side effect of their medication. By identifying brain differences, doctors hope to personalize treatment and reduce these risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 44 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 45 to 80 years * Patients diagnosed with idiopathic Parkinson's disease (PD) according to the Movement Disorder Society criteria * Duration of Parkinson's disease progression ≥ 3 years * Patients receiving chronic dopaminergic treatment including levodopa for at least one year to avoid tolerance issues during acute levodopa administration * Ability to cooperate and understand, allowing strict compliance with the conditions set forth in the protocol * Patients affiliated with or beneficiaries of a social security system * Volunteer patients capable of providing informed consent to participate in the research Exclusion Criteria: * Patients suffering from neurological disorders other than idiopathic Parkinson's disease (PD) * Patients with severe depression (Beck Depression Inventory \\\[20\] (BDI) score \> 30), apathy (Starkstein scale \\\[21\] score ≥ 14), cognitive impairment (Montreal Cognitive Assessment \\\[MoCA\] \\\[22\] score \< 25). * Patients with impulse control disorders, defined by either of the following: * A score of ≥ 6 on the "Pathological Gambling" item, ≥ 8 on the "Compulsive Buying" item, ≥ 8 on the "Sexual Behavior" item, or ≥ 7 on the "Eating Behavior" item, and more than one positive response (score \> 0) on the corresponding QUIP-RS items for Gambling, Compulsive Buying, Sexual Behavior, and Eating Behavior. * A total QUIP-RS score ≥ 10. * Patients with severe motor symptoms: patients with an MDS-UPDRS III score \> 45 will be excluded to avoid severe discomfort or interfering tremor (tremor item ≥ 3 in any body part) in the OFF state during PET-MRI acquisition. Patients with severe dyskinesias will also be excluded due to technical issues related to movement * Patients under guardianship, curatorship, deprived of liberty, or under legal protection * Pregnant or breastfeeding women * Patients with contraindications to PET-MRI (e.g., those with pacemakers or insulin pumps, metallic prostheses or intracerebral clips, claustrophobia, neurosensorial stimulators or implantable defibrillators, cochlear implants, ferromagnetic ocular or cerebral foreign bodies near nervous structures, uncooperative or agitated patients, neurosurgical ventriculoperitoneal shunts, dental appliances) * Refusal to participate
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson'S disease (PD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CH Le Puy en Velay
RECRUITINGLe Puy-en-Velay, France
-
CHRU Lyon
RECRUITINGLyon, France
-
CHU Clermont-Ferrand, Clermont-Ferrand,
RECRUITINGClermont-Ferrand, 63000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a mediterranean diet and exercise ease Parkinson's by reshaping the gut?
- CBD oil shows promise for easing anxiety and depression in Parkinson's patients
- Could a Brain-Healthy diet help fight ALS and Parkinson's?
- Parkinson's treatment could go monthly: new injection tested
- Smartphone beats could steady Parkinson's steps
- Parkinson's patients get new hope: group therapy targets anxiety and depression